About the Company
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MNK News
Bankruptcy allowed Mallinckrodt to end Acthar royalties, 3rd Circ. rules
Mallinckrodt's bankruptcy permitted the drug company to end a perpetual royalty agreement with Sanofi-Aventis involving the ...
Mallinckrodt plc v. Airgas Therapeutics LLC - INOmax® (Nitric Oxide)
Case Name: Mallinckrodt plc v. Airgas Therapeutics LLC, Civ No. 22-1648-RGA, 2024 WL 1251260 (D. Del. Mar. 22, 2024) (Andrews, J.) Drug Product and Patent(s)-in-Suit ...
Mallinckrodt PLC Ordinary Shares - New
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Mallinckrodt gets grant for filter apparatus for liquid removal from gas
Discover Mallinckrodt Plc's innovative patent for a filter apparatus removing liquid from gas efficiently. Learn about the unique features and benefits of this groundbreaking technology.
Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.
Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, today announced the successful completion of its acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ:CADX ...
Mallinckrodt plc: Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 ...
Next PLC
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Adient plc (ADNT)
Adient plc (NYSE:ADNT) Q2 2024 Earnings Call Transcript May 3, 2024 Adient plc misses on earnings expectations. Reported EPS is $0.31 EPS, expectations were $0.39. Adient plc isn’t one of the 30 ...
Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 ...
Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
Part of Mallinckrodt's ongoing commitment to the science of immunomodulation through ECP is to recognize individuals and institutions whose research contributes to the advancement of knowledge in ...
Loading the latest forecasts...